AIM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-0.940

-90.6%

0.00

-100%

-1.080

-78.4%

0.00

-100%

-1.080

-70.65%

Estimates Revision

The market is revising No Change the revenue expectations for AIM ImmunoTech Inc. (AIM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -50.53%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-50.53%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 15.00 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.00

Averages

15.00

High

24.00

Current: 0.000

Low

6.00

Averages

15.00

High

24.00

No data

Valuation Metrics

The current forward P/E ratio for AIM ImmunoTech Inc (AIM.A) is -0.28, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess AIM ImmunoTech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.08

Current PE

-0.28

Overvalued PE

-0.10

Undervalued PE

-4.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

232.79

Current PS

0.00

Overvalued PS

442.00

Undervalued PS

23.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AIM News & Events

Events Timeline

No data

News

8.0

2025-12-30Globenewswire

AIM ImmunoTech Declares 1-for-1000 Stock Dividend for Shareholders

8.0

2025-12-30Newsfilter

AIM ImmunoTech Declares 1-for-1000 Stock Dividend for Shareholders

9.5

2025-12-29Yahoo Finance

Ai-Media Technologies (ASX:AIM) Shares Up 111% Over Three Years Despite 12% Quarterly Drop

People Also Watch

Frequently Asked Questions

What is AIM ImmunoTech Inc (AIM) stock price today?

The current price of AIM is 1.29 USD — it has decreased -3.66 % in the last trading day.

What is AIM ImmunoTech Inc (AIM)'s business?

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

What is the price predicton of AIM Stock?

What is AIM ImmunoTech Inc (AIM)'s revenue for the last quarter?

AIM ImmunoTech Inc revenue for the last quarter amounts to 26.00K USD, decreased -25.71 % YoY.

What is AIM ImmunoTech Inc (AIM)'s earnings per share (EPS) for the last quarter?

AIM ImmunoTech Inc. EPS for the last quarter amounts to -1.57 USD, decreased -75.55 % YoY.

What changes have occurred in the market's expectations for AIM ImmunoTech Inc (AIM)'s fundamentals?

How many employees does AIM ImmunoTech Inc (AIM). have?

AIM ImmunoTech Inc (AIM) has 21 emplpoyees as of January 09 2026.

What is AIM ImmunoTech Inc (AIM) market cap?

Today AIM has the market capitalization of 3.91M USD.